Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Correction

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan

  • Hitoshi Tajiri,
  • Satoshi Motoya,
  • Fukunori Kinjo,
  • Atsuo Maemoto,
  • Takayuki Matsumoto,
  • Noriko Sato,
  • Hiroshi Yamada,
  • Mieko Nagano,
  • Yutaka Susuta,
  • Kunihiko Ozaki,
  • Kazuoki Kondo,
  • Toshifumi Hibi

An incorrect version of S1 File was published as two separate Supporting Information documents (S1 and S2 Files in the original article) in error. Please view the correct S1 File below.

Supporting information

S1 File. Protocol summary in English.

https://doi.org/10.1371/journal.pone.0261932.s001

(PDF)

Reference

  1. 1. Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, et al. (2018) Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS ONE 13(8): e0201956. pmid:30114224

Citation: Tajiri H, Motoya S, Kinjo F, Maemoto A, Matsumoto T, Sato N, et al. (2022) Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan. PLoS ONE 17(4): e0261932. https://doi.org/10.1371/journal.pone.0261932

Published: April 19, 2022

Copyright: © 2022 Tajiri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.